The overall goal of the Clinical Core is to generate data and biospecimens required to support high quality, cutting edge, externally-funded clinical and clinical-pathologic studies that focus on the full spectrum of cognition from normal aging to mild cognitive impairment (MCI) to the earliest stages of dementia among older African Americans. Historically, progress in Alzheimer's disease (AD) research has been most striking among members of the U.S. non-Hispanic white population. However, because of the expected increase in the growth of the older African American population, because African Americans may be at greater risk of AD than whites, and the burden of AD and mixed dementias is projected to increase dramatically for this population, the Rush Clinical Core will focus on enrolling and following African Americans longitudinally to accomplish the following Specific Aims: 1) Continue to recruit and enroll African Americans without dementia who agree to annual, detailed clinical evaluations and collection of ante-mortem biologic specimens;2) Continue to conduct uniform structured baseline and annual follow-up evaluations, including neurological examination and neuropsychological performance testing, of community-dwelling Clincal Core participants, apply uniform diagnostic criteria for incident AD, MCI, and mixed dementias as specified in the UDS, and supplement UDS data collection with an extended battery of tests to increase compatibility with the Religious Orders Studies Core;3) Integrate innovative and culturally tailored educational programs into the clinical evaluation to increase awareness of the importance of brain autopsy in African Americans and to facilitate a high autopsy rate with a short post-mortem interval;and continue to harvest and preserve the brain tissue in a fashion that retains maximum flexibility to support a diverse array of studies;and 4) Increase capacity to conduct externally funded clinical, neuropsychological, and clinical-pathological research studies, including studies that incorporate contemporary biochemical and molecular techniques, by contributing data to NACC and providing an environment and resources to facilitate entry of subjects, clinical data, and post-mortem tissue into research projects at Rush and within the AD research community at large.

Public Health Relevance

The Rush Clinical Core will generate data and biospecimens to support high quality, cutting edge clinical and clinical-pathologic studies that focus on the full spectrum of cognition in older African Americans, one of the fastest growing populations in the U.S. Knowledge gained through studies supported by the Core will advance our understanding of the clinical and neuropathoiogic transitions from normal cognition to dementia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010161-23
Application #
8494477
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
23
Fiscal Year
2013
Total Cost
$345,361
Indirect Cost
$119,635
Name
Rush University Medical Center
Department
Type
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
Kovaleva, Mariya A; Bilsborough, Elizabeth; Griffiths, Patricia C et al. (2018) Testing Tele-Savvy: Protocol for a randomized controlled trial. Res Nurs Health 41:107-120
Mahady, L; Nadeem, M; Malek-Ahmadi, M et al. (2018) HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease. Neuropathol Appl Neurobiol :
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Sekiya, Michiko; Wang, Minghui; Fujisaki, Naoki et al. (2018) Integrated biology approach reveals molecular and pathological interactions among Alzheimer's A?42, Tau, TREM2, and TYROBP in Drosophila models. Genome Med 10:26
Kommaddi, Reddy Peera; Das, Debajyoti; Karunakaran, Smitha et al. (2018) A? mediates F-actin disassembly in dendritic spines leading to cognitive deficits in Alzheimer's disease. J Neurosci 38:1085-1099
Mahady, Laura; Nadeem, Muhammad; Malek-Ahmadi, Michael et al. (2018) Frontal Cortex Epigenetic Dysregulation During the Progression of Alzheimer's Disease. J Alzheimers Dis 62:115-131
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Wang, Dai; Schultz, Tim; Novak, Gerald P et al. (2018) Longitudinal Modeling of Functional Decline Associated with Pathologic Alzheimer's Disease in Older Persons without Cognitive Impairment. J Alzheimers Dis 62:855-865
Boyle, Patricia A; Yu, Lei; Wilson, Robert S et al. (2018) Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol 83:74-83

Showing the most recent 10 out of 786 publications